Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity

Metallo-β-lactamase (MBL)-producing Gram-negative bacteria cause infections associated with high rates of morbidity and mortality. Currently, a leading regimen to treat infections caused by MBL-producing bacteria is aztreonam combined with ceftazidime-avibactam. ABSTRACT Metallo-β-lactamase (MBL)-producing Gram-negative bacteria cause infections associated with high rates of morbidity and mortality. Currently, a leading regimen to treat infections caused by MBL-producing bacteria is aztreonam combined with ceftazidime-avibactam. The purpose of the present study was to evaluate and rationally optimize the combination of aztreonam and ceftazidime-avibactam with and without polymyxin B against a clinical Klebsiella pneumoniae isolate producing NDM-1 and CTX-M by use of the hollow fiber infection model (HFIM). A novel de-escalation approach to polymyxin B dosing was also explored, whereby a standard 0-h loading dose was followed by maintenance doses that were 50% of the typical clinical regimen. In the HFIM, the addition of polymyxin B to aztreonam plus ceftazidime-avibactam significantly improved bacterial killing, leading to eradication, including for the novel de-escalation dosing strategy. Serial samples from the growth control and monotherapies were explored in a Galleria mellonella virulence model to assess virulence changes. Weibull regression showed that low-level ceftazidime resistance and treatment with monotherapy resulted in increased G. mellonella mortality (P < 0.05). A neutropenic rabbit pneumonia model demonstrated that aztreonam plus ceftazidime-avibactam with or without polymyxin B resulted in similar bacterial killing, and these combination therapies were statistically significantly better than monotherapies (P < 0.05). However, only the polymyxin B-containing combination therapy produced a statistically significant decrease in lung weights (P < 0.05), indicating a decreased inflammatory process. Altogether, adding polymyxin B to the combination of aztreonam plus ceftazidime-avibactam for NDM- and CTX-M-producing K. pneumoniae improved bacterial killing effects, reduced lung inflammation, suppressed resistance amplification, and limited virulence changes.

[1]  F. Mancia,et al.  CrrB Positively Regulates High-Level Polymyxin Resistance and Virulence in Klebsiella pneumoniae , 2020, Cell reports.

[2]  D. Landman,et al.  Cefiderocol Resistance in Acinetobacter baumannii: Roles of β-Lactamases, Siderophore Receptors, and Penicillin Binding Protein 3 , 2020, Antimicrobial Agents and Chemotherapy.

[3]  V. Fowler,et al.  Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model. , 2020, The Journal of antimicrobial chemotherapy.

[4]  R. Nation,et al.  In Pursuit of the triple Crown: mechanism-based pharmacodynamic modeling for the optimization of 3-drug combinations against KPC-Producing Klebsiella pneumoniae. , 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[5]  C. Landersdorfer,et al.  Using machine learning to optimise antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii. , 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[6]  R. Bonomo,et al.  Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five β-Lactams Simultaneously in Carbapenem-Resistant Klebsiella pneumoniae and Enterobacter cloacae , 2020, mBio.

[7]  T. Walsh,et al.  Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits , 2020, Antimicrobial Agents and Chemotherapy.

[8]  K. Verstrepen,et al.  Enrichment of persisters enabled by a ß-lactam-induced filamentation method reveals their stochastic single-cell awakening , 2019, Communications Biology.

[9]  Antibiotic resistance threats in the United States, 2019 , 2019 .

[10]  C. Schofield,et al.  Profiling interactions of vaborbactam with metallo-β-lactamases , 2019, Bioorganic & medicinal chemistry letters.

[11]  Brian T. Tsuji,et al.  Rational Combinations of Polymyxins with Other Antibiotics. , 2019, Advances in experimental medicine and biology.

[12]  Z. Zong,et al.  In-hospital Medical Costs of Infections Caused by Carbapenem-resistant Klebsiella pneumoniae. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  R. Bonomo,et al.  Carbapenemase-Producing Organisms: A Global Scourge. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  M. Ouellette,et al.  Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. , 2017, The Lancet. Infectious diseases.

[15]  Qi Zhao,et al.  Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to Enterobacteriaceae: Results of a Systematic Literature Review and Meta-analysis , 2016, Open forum infectious diseases.

[16]  R. Nation,et al.  Pharmacodynamics of dose-escalated ‘front-loading’ polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli , 2017, The Journal of antimicrobial chemotherapy.

[17]  J. Li,et al.  Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and blaNDM-5: Preparation for a Postantibiotic Era , 2017, mBio.

[18]  D. van Duin,et al.  Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy , 2017, Drugs.

[19]  Diansong Zhou,et al.  Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis , 2017, Journal of clinical pharmacology.

[20]  R. Humphries,et al.  Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? , 2017, Antimicrobial Agents and Chemotherapy.

[21]  Brian T. Tsuji,et al.  High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model , 2017, Antimicrobial Agents and Chemotherapy.

[22]  Zhongheng Zhang,et al.  Parametric regression model for survival data: Weibull regression model as an example. , 2016, Annals of translational medicine.

[23]  E. Chan,et al.  Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model , 2016, Antimicrobial Agents and Chemotherapy.

[24]  Brian T. Tsuji,et al.  Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii , 2016, Antimicrobial Agents and Chemotherapy.

[25]  W Wang,et al.  A Tutorial on RxODE: Simulating Differential Equation Pharmacometric Models in R , 2015, CPT: pharmacometrics & systems pharmacology.

[26]  David A. James,et al.  Facilities for Simulating from ODE-Based Models , 2015 .

[27]  A. Tarral,et al.  Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Avibactam Alone and in Combination with Ceftazidime in Healthy Male Volunteers: Results of Two Randomized, Placebo-Controlled Studies , 2015, Clinical Drug Investigation.

[28]  Björn Usadel,et al.  Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..

[29]  K. Rufibach,et al.  SurvRegCensCov: Weibull Regression for a Right-Censored Endpoint with a Censored Covariate , 2014, 1402.0432.

[30]  C. Landersdorfer,et al.  Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[31]  C. Landersdorfer,et al.  Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. , 2013, The Journal of antimicrobial chemotherapy.

[32]  Pablo Cingolani,et al.  © 2012 Landes Bioscience. Do not distribute. , 2022 .

[33]  M. Neely,et al.  Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. , 2011, Current pharmaceutical biotechnology.

[34]  Gonçalo R. Abecasis,et al.  The variant call format and VCFtools , 2011, Bioinform..

[35]  Jurgen Bernd Bulitta,et al.  Development of a New Pre- and Post-Processing Tool (SADAPT-TRAN) for Nonlinear Mixed-Effects Modeling in S-ADAPT , 2011, The AAPS Journal.

[36]  Clsi.  Performance Standards for Antimicrobial Susceptibility Testing: Twenty-First Informational Supplement , 2010 .

[37]  Neang S. Ly,et al.  Attenuation of Colistin Bactericidal Activity by High Inoculum of Pseudomonas aeruginosa Characterized by a New Mechanism-Based Population Pharmacodynamic Model , 2010, Antimicrobial Agents and Chemotherapy.

[38]  U. Holzgrabe,et al.  Population Pharmacokinetic Comparison and Pharmacodynamic Breakpoints of Ceftazidime in Cystic Fibrosis Patients and Healthy Volunteers , 2010, Antimicrobial Agents and Chemotherapy.

[39]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[40]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[41]  S. Hultgren,et al.  Filamentation by Escherichia coli subverts innate defenses during urinary tract infection , 2006, Proceedings of the National Academy of Sciences.

[42]  Max Salfinger,et al.  Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. , 2004, The Journal of infectious diseases.

[43]  Stanley N Cohen,et al.  SOS Response Induction by ß-Lactams and Bacterial Defense Against Antibiotic Lethality , 2004, Science.

[44]  Edward R. B. Moore,et al.  Bacterial Filament Formation, a Defense Mechanism against Flagellate Grazing, Is Growth Rate Controlled in Bacteria of Different Phyla , 1999, Applied and Environmental Microbiology.

[45]  T. Walsh,et al.  Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. , 1988, Laboratory animal science.

[46]  J. Blaser.  In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. , 1985, The Journal of antimicrobial chemotherapy.

[47]  R. Sykes,et al.  Mode of action of azthreonam , 1982, Antimicrobial Agents and Chemotherapy.